ReviewTropical medicine and infectious disease2023
Post-Artesunate Delayed Hemolysis: A Review of Current Evidence.
Review in Tropical medicine and infectious disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Construction of Sulfhydryl-Amino UiO-66/PVDF Membranes via Morphology Regulation for the Selective Separation of Artesunate.Molecules (Basel, Switzerland) · 2026Article
- Host-directed therapeutic strategies against apicomplexan parasites: targeting purinergic P2 receptors.Purinergic signalling · 2026Review
- Article
- Single-step versus conventional injectable artesunate for severe malaria in children: an open label, non-inferiority randomized clinical trial, Democratic Republic of the Congo and United Republic of Tanzania.Bulletin of the World Health Organization · 2026Article
- Spectrophotometric analysis of artesunate injections available in community pharmacies in Northern and Western Uganda.Future science OA · 2025Article
- Malaria.The New England journal of medicine · 2025Review
- Post-Artesunate Delayed Hemolysis: Anything That Can Go Wrong Will Go Wrong-Murphy's Law.Clinical case reports · 2025Article
- Inhibition of Complement Will Substantially Reduce the Anemia of Malaria.Journal of immunology research · 2025Review
- Antimalarial and neuroprotective effects of ethanolic extracts of the five-flower remedy in an experimental cerebral malaria model.PloS one · 2025Article
- Defining the next generation of severe malaria treatment: a target product profile.Malaria journal · 2024Review
- An old foe on peculiar paths: severe falciparum malaria in a Syrian refugee, possibly infected during migrant smuggling from Türkiye to Germany.Infection · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed hemolysis (PADH) is an uncommon adverse event from malaria treatment. Most patients with PADH are non-immune travelers. The pathophysiology of PADH is not fully understood, but the most likely mechanism is "pitting", in which red blood cells carrying dead parasites killed by artesunate's action are directed to the spleen for clearing the dead parasites. After the cleansing process, these red blood cells re-enter the circulation but with a smaller size and impaired integrity, resulting in a shortened lifespan of 7-21 days. Therefore, most patients with PADH usually present with clinical features of hemolytic anemia 7 days or later after the initiation of artesunate. To date, the benefits of artesunate treatment outweigh its adverse events, and no fatal cases have resulted from PADH. However, the hematological follow-up of patients with malaria treated with artesunate is recommended for clinicians to detect any delayed hemolytic event early and prevent potentially serious consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.